The UK and US have hammered out a key commercial pact that will ensure zero levies on UK drug exports being sold in the American market.
The Terms of the Pact
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the public health system. This move ensures that import taxes on these vital exports will stay at nothing for a duration of 36 months.
This deal follows earlier threats to hike tariffs on branded pharmaceutical imports, with figures discussed up to 100%.
"This deal between the Britain bolsters the global environment for innovative medicines and brings long-overdue equity to American-British drug exports," a release declared.
Trade Impact
Pharmaceuticals are one of the Britain's biggest exports to the America, which is clearly the largest market for leading British pharmaceutical firms.
Export figures show that in the one-year period prior to last September, the UK exported drugs valued at billions to the US. This value accounted for 17.4% of British export trade in that period.
"This agreement secures work, increases capital expenditure and paves the way for the UK to establish itself as a global hub for medical research," a minister stated.
Key UK Commitments
The agreement includes several notable changes from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to increase total public funding on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. In the past, repayments topped twenty percent.
Industry Background
The pact takes place against a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
This friction were intensified by assertions that American consumers were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the last ten years.
